Engineering immune cells to fight cancer using virus-like particles
Cancer therapy by targeting innate immune cells in vivo using novel virus-like particles
['FUNDING_R21'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-11113643
This study is testing a new gene therapy that helps immune cells better fight cancer, aiming to create a ready-made treatment that can be used by many patients without needing to customize it for each person.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11113643 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel gene therapy that enhances the ability of immune cells, such as T cells, NK cells, and macrophages, to target and destroy cancer cells. By using virus-like particles, the researchers aim to create a more efficient and standardized method for producing these engineered immune cells, which can potentially be used as an 'off-the-shelf' treatment for various cancers. This approach seeks to overcome the limitations of current therapies that require patient-specific cell manufacturing, making treatment more accessible and affordable for a broader range of patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with refractory cancers, particularly those who have not responded to traditional therapies.
Not a fit: Patients with early-stage cancers or those who are not candidates for immune cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and accessible cancer treatment option for patients with difficult-to-treat malignancies.
How similar studies have performed: Previous research has shown promise in using engineered immune cells for cancer treatment, particularly with CAR-T therapies, indicating a potential for success with this novel approach.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAUFMAN, DAN S. — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: KAUFMAN, DAN S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.